Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved crawled date : 2022 - 06 - 23 save search
POLY ANNOUNCES STOCKHOLDER APPROVAL OF MERGER AGREEMENT WITH HP INC.
Published: 2022-06-23 (Crawled : 21:00) - prnewswire.com
HPQ | $27.81 0.69% 0.0% 4.8M
|
Electronic Technology
|
| O: 1.15%
H: 2.92%
C: 2.83%
approval agreement
Landmark Plan to Accelerate End of Coal Era, Provide Reliability and Protect Environment Earns Approval
Published: 2022-06-23 (Crawled : 20:00) - prnewswire.com
CMS | $59.55 1.83% 0.0% 1.7M
|
Utilities
|
| O: 0.45%
H: 1.68%
C: 1.21%
approval
Points Shareholders Approve Arrangement With Plusgrade
Published: 2022-06-23 (Crawled : 18:00) - globenewswire.com
PCOM | $24.99 0.08% 0.0%
|
Commercial Services
|
| O: 0.16%
H: 0.24%
C: 0.16%
Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio
Published: 2022-06-23 (Crawled : 14:00) - globenewswire.com
PVCT 4 | $0.195 -15.0% 56K
|
Manufacturing
|
| O: 3.77%
H: 10.73%
C: 10.73%
authorized approval
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-06-23 (Crawled : 13:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.09%
H: 3.99%
C: 3.0%
CNSP | $0.1934 -5.2% -5.48% 87K
|
Health Technology
|
| O: 32.07%
H: 1.89%
C: -24.85%
treatment fda ongoing trial approval berubicin potential
European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB
Published: 2022-06-23 (Crawled : 13:00) - biospace.com/
AMYT | $14.7 0.0% 2.4M
|
Health Technology
|
| O: 3.33%
H: 0.0%
C: 0.0%
filsuvez treatment
Fusion Fuel Projects Approved to Receive Financing Awards from Portugal’s C-05 Mobilizing Agendas for Business Innovation
Published: 2022-06-23 (Crawled : 09:00) - globenewswire.com
HTOO | $1.28 -2.29% -2.34% 52K
|
|
| O: 0.0%
H: 2.86%
C: 0.29%
awards approved innovation
Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors
Published: 2022-06-22 (Crawled : 00:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
fda novartis approval tafinlar
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.